The Latest Breaking News from Clinical Trial

Summary Delcath Systems (DCTH) shows strong technical buy signals, with a 53.41% gain since 1/25 and a 271.33% gain in the last year. The company focuses on liver cancer treatments, with its leading product HEPZATO KIT and ongoing FOCUS clinical trial for metastatic uveal melanoma. Barchart indicators highlight 100% technical...

With positive results from a clinical trial targeting Type 1 diabetes, Wall Street is feeling hot on this little biotech stock.

Up to 21 million people contract norovirus each year in the U.S. alone, the CDC says.

PROSTATE cancer imaging developed by university researchers has shown “extremely encouraging” results in its first clinical trials...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

The vaccine works by harnessing a patient’s own immune system to attack and destroy cancer.

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables.

Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head-to-head study.

IGC Pharma, Inc.(NYSE:IGC) reported additional interim data from its ongoing Phase 2 clinical trial evaluating IGC-AD1 for agitation in dementia associated with Alzheimer's disease. IGC-AD1 targets neuro-inflammation and CB1 receptor dysfunction,. The investigational drug contains THC as one of two active pharmaceutical agents. 

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular degeneration that causes vision loss in millions of older people worldwide.

London hospital is leading a new clinical trial to treat glioblastoma